The relevant distinction between "progression" in ovarian cancer drug trials and the clinical decision to change therapy.
Markman
Maurie
M
Department of Gynecologic Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. maurie.markman@ctca-hope.com